Short Interest in Ainos, Inc. (NASDAQ:AIMD) Decreases By 72.8%

Ainos, Inc. (NASDAQ:AIMD) saw a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 99,130 shares, a decrease of 72.8% from the January 29th total of 364,031 shares. Based on an average trading volume of 129,496 shares, the days-to-cover ratio is presently 0.8 days. Approximately 2.3% of the company’s stock are sold short. Approximately 2.3% of the company’s stock are sold short. Based on an average trading volume of 129,496 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Ainos in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Ainos Price Performance

AIMD opened at $1.66 on Friday. The firm has a market capitalization of $7.98 million, a PE ratio of -0.42 and a beta of 2.50. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.96 and a quick ratio of 2.67. The business’s 50-day moving average is $1.81 and its two-hundred day moving average is $2.71. Ainos has a 1 year low of $1.26 and a 1 year high of $4.50.

Insider Transactions at Ainos

In other Ainos news, major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $2.17, for a total transaction of $99,820.00. Following the transaction, the insider owned 989,925 shares of the company’s stock, valued at approximately $2,148,137.25. This trade represents a 4.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 47,281 shares of company stock worth $102,152. 9.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ainos

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mariner LLC acquired a new stake in Ainos in the fourth quarter valued at approximately $37,000. Two Sigma Investments LP purchased a new stake in shares of Ainos during the 3rd quarter valued at $80,000. DRW Securities LLC boosted its position in shares of Ainos by 272.6% in the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after purchasing an additional 48,439 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Ainos by 13.1% during the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after buying an additional 7,700 shares during the last quarter.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.